Browsing: GLP1

Millions of people in the U.S. are taking injectable GLP-1 drugs for weight loss, and now there is even a CMS subsidy for certain GLP-1 medications. But the drug hasn’t had much of an impact on senior living operations or residents thus far

As Ozempic’s popularity soared in the early 2020s, its eye-popping cost — more than $1,000 for a month’s supply, in some cases — made headlines. With more GLP-1 options now on the market, broader insurance coverage for the drugs to treat additional conditions and the proliferation of cheaper compounded versions, prices have slowly begun to…

A panel discussion on Barron’s Roundtable examined the expanding use of GLP-1 medications beyond weight loss, exploring new medical applications, potential side effects, and the implications of the next generation of these drugs for patients

A panel examines the expansion of GLP-1 medications beyond weight loss, exploring new medical uses, potential side effects and what the next wave of these blockbuster drugs could mean for patients on ‘Barron’s Roundtable.’

The Medicines and Healthcare products Regulatory Agency confirmed on 10 August that it had authorised orforglipron, sold under the brand name Foundayo, making Britain the first country in Europe to licence an oral GLP-1 receptor agonist for both weight management and type 2 diabetes. Julian Beach, the MHRA’s executive director of healthcare quality and access,…

For as long as they can remember, sisters Karon Richardson and Nikki James have shared many things, including a lifelong struggle with their weight. After years of trying just about every diet under the sun and watching the pounds return, both women turned to bariatric surgery. The procedures helped them lose weight and regain confidence,…

Background: The popularity of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has increased significantly in recent years, raising concerns about self-medication with these medications. Objective: To assess the proportion and identify factors associated with GLP-1 RA use without medical prescription among GLP-1 RA users in Brazil. Methods: This cross-sectional study was conducted through a…

Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D) and Zepbound for obesity. The two tirzepatide-based therapies continued to drive Lilly’s top-line performance in the second quarter of 2026. Mounjaro generated $9.94 billion in worldwide revenues, up 91% year over year, while Zepbound sales increased 46%…

WASHINGTON — Chances are you’ve seen the ads promoting cheaper weight-loss shots, no insurance required, delivered straight to your door. They’re everywhere you look right now, from social media to late-night TV

The GHA is considering whether to offer oral GLP-1 weight-loss drugs, with the service expected to change significantly within the next decade as new treatments become available, the Director of Public Health, Dr Helen Carter, has said